Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
HNJrkf9BBstnWY0M
Écouter
